Going beyond the BRCA1/2 genes for breast cancer risk w/ Kevin Haas
In this episode of Data Unchained, Molly Presley talks with Kevin Haass, CTO of Myriad Genetics, about how genomics, large scale sequencing and modern cloud architectures are reshaping precision medicine. Haass explains how genetic testing has evolved from early discoveries like BRCA1 and BRCA2 into a broad ecosystem that supports cancer risk assessment, prenatal care and mental health treatment. He describes how the industry processes millions of tests each year using next generation sequencing labs, automation, robotics and globally distributed cloud compute. Haass outlines the full path fr…